Clinical Utility of 18F-FDG PET/CT Concurrent with 131I Therapy in Intermediate–to–High-Risk Patients with Differentiated Thyroid Cancer: Dual-Center Experience with 286 Patients

• DOI: 10.2967/jnumed.112.117119
• Publication Date: 2013-06-29T07:23:14Z
• Authors: Jeong Won Lee; Sang Mi Lee; Dae Ho Lee; Yeo Joo Kim
• Keywords: Ablation Therapy; Single Center; Adjuvant Therapy

Patients with differentiated thyroid carcinoma (DTC) are treated ¹³¹I therapy after total thyroidectomy or surgical resection of recurrent tumor. However, some DTC lesions not iodine-avid, which affects further treatment planning. The aim this study was to evaluate the clinical benefit ¹⁸F-FDG PET/CT performed concurrently in patients intermediate high risk. <b>Methods:</b> We retrospectively enrolled 286 at 2 Korean medical centers who comprised different patient groups: 28 underwent adjuvant curative tumor and 258 risk ablation thyroidectomy. scanning were on same day. Administration l-thyroxine withheld from all enrollees for 4 wk before treatment. <b>Results:</b> In 39 (14%), detected additional metastatic that posttherapy scan, plan changed 30 (10%) based such findings. Among receiving tumor, 46%, 43%. Assessing a subgroup stage T3–T4N1 size &gt; 2.0 cm, among undergoing thyroidectomy, we found 25% had positive results, 17%. contrast, 8% ≤ 6% T1–T2N1 patients, 3% T3–T4N0 <b>Conclusion:</b>¹⁸F-FDG 14% particularly helpful detecting cm.